CELC
Celcuity Inc.
NASDAQ · Healthcare · Biotechnology · US
$56.58
−6.17%Price chart
Sep 17Sep 22Sep 25Sep 30Oct 5Oct 8Oct 13Oct 16
Key dataOct 16, 2026
Open$60.16
From 52W high−60.97%
Volume4.31M
Market cap$2.77B
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataOct 16, 2026
Open
$60.16
From 52W high
−60.97%
Volume
4.31M
Market cap
$2.77B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−14.9x
P/E (TTM)
—
RSI (14)
21.1
MomentumView details →
1D Return
−6.17%
YTD Return
−44.44%
SummaryUpdated Jun 1, 2026
Celcuity Inc. (NASDAQ:CELC) is a clinical-stage biotechnology company founded in 2011 and headquartered in Minneapolis, Minnesota. The company went public in September 2017 and focuses on developing molecularly targeted cancer therapies. Celcuity operates through two main platforms: its lead drug candidate <b>gedatolisib</b>, which targets multiple cancer pathways simultaneously, and its proprietary <b>CELsignia diagnostic platform</b> that uses living tumor cells to identify specific cellular processes driving individual patients' cancers. The company is currently in late-stage clinical trials with potential regulatory approval on the horizon for 2025-2026.
Similar companies
Latest newsMore news →
Celcuity Inc. announced that a late-breaking rapid oral presentation and three poster presentations on its gedatolisib clinical trial data will be featured at the ESMO Congress 2026, to be held October 23-27, 2026, in Madrid, Spain.14d agoCelcuity Inc. appointed David W. Gryska as a director effective October 1, 2026, with an annual base salary of $70,000 and a pro-rated grant of 893 restricted stock units.17d ago